AbbVie recently announced positive results for the company’s investigational regimen of glecaprevir/pibrentasvir (G/P) in treating patients with chronic hepatitis C virus (HCV). Results are from the EXPEDITION-4 study (NCT02651194), an open-label Phase ... Read more